drugset / Trial / NCT00057447
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Timeline
- Start
- 2003-03
- Primary completion
- —
- Completion
- 2004-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon gamma-1b | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Subject | Interferon gamma-1b | Protein / enzyme biologic | 200 ug | Subcutaneous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |